ELCC 2022 Highlights Podcast

In this episode (21:43 min), Medicom’s correspondent covers 6 presentations from the European Lung Cancer Congress (ELCC 2022) which was held virtually this year with over 2,200 participants from over 95 countries, between the 30th March- 2nd April 2022.

1. Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
   In the phase 3 FURLONG study, third-generation tyrosine kinase inhibitor (TKI) furmonertinib significantly prolonged progression-free survival (PFS) in patients with treatment-naïve, EGFR-mutated, stage IIIB-IV non-small cell lung cancer (NSCLC), compared with gefitinib.
2. Sintilimab plus chemotherapy improves OS in treatment-naïve stage III/IV non-squamous NSCLC
   The final results of the phase 3 ORIENT-11 trial show improved overall survival (OS) in patients with treatment-naïve stage III/IV non-squamous non-small cell lung cancer (NSCLC) treated with sintilimab plus chemotherapy versus placebo plus chemotherapy.
3. In concurrent chemoradiotherapy for stage III, unresectable NSCLC, proton-therapy bests photon therapy
   In a Dutch study, performance status after concurrent chemoradiotherapy was better if patients were treated with protons than with photons, potentially increasing eligibility for adjuvant durvalumab.
4. Characteristics of long-term survivors in the CASPIAN trial
   Long-term survivors in the CASPIAN trial share common favourable – and potentially predictive – clinical and molecular characteristics. This was demonstrated in a subanalysis of the phase 3 trial investigating durvalumab in extensive-stage small cell lung cancer (ES-SCLC).
5. Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
   The phase 3 POSEIDON study previously showed that addition of immunotherapy (durvalumab or durvalumab/tremelimumab) to chemotherapy improved survival of patients with metastatic non-small cell lung cancer. Patient-reported outcomes now indicate that deterioration of health-related quality of life is delayed.
6. No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
   Although the addition of ipilimumab to first-line nivolumab improved survival of patients with metastatic NSCLC, long-term results from KEYNOTE-598 show that adding ipilimumab to first-line pembrolizumab does not improve survival of patients with metastatic NSCLC and PD-L1 ≥50%.

Enjoy listening!

 

Copyright ©2022 Medicom Medical Publishers



Posted on 19 April 202227 June 2024